Tofacitinib versus standard of care treatment in patients with COVID-19:
a multicenter non-randomized controlled study
Sergey Moiseev,1 Nikolay Bulanov,1Anastasiia Zykova,2 Michail Brovko,1Pavel Novikov,1 Larisa Akulkina,1Natalya Chichkova,3 Natalya
Trushenko,4 Maria Lukina,5 Yuriy
Sorokin,1 Ekaterina Tao,1 Ekaterina
Filatova,1 Aram Kitbalyan,1,2 Pavel
Potapov,1,2 Lubov Ermolova,1 Olga
Suvorova,4 Augusto Vaglio,6 Andreas
Kronbichler,7 Sergey Avdeev,4 Victor
Fomin3
1Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical
University, Moscow, Russia,
2Department of Internal Medicine, Lomonosov Moscow State University,
Moscow, Russia,
3Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State
Medical University, Moscow, Russia,
4Clinic of Pulmonology, Sechenov First Moscow State Medical University,
Moscow, Russia,
5Department of Clinical Pharmacology and Internal Diseases, Sechenov
First Moscow State Medical University, Moscow, Russia
6Department of Biomedical Experimental and Clinical Sciences “Mario
Serio”, University of Firenze, and Nephrology Unit, Meyer Children’s
Hospital, Firenze, Italy,
7Department of Medicine, University of Cambridge, Cambridge, United
Kingdom
Running title: Tofacitinib for COVID-19 pneumonia